Personalized approaches in phage therapy of multidrug-resistant infections
DOI:
https://doi.org/10.5281/zenodo.14275730Keywords:
bacteriophages, phage therapy, phage banksAbstract
The global spread of infections caused by multidrug-resistant microorganisms highlights the importance of discovering and developing new antimicrobial agents. Bacteriophages, including the strategy of their combined use with antibiotics, may serve as an additional element in the fight against antibiotic-resistant microorganisms. Bacteriophages have been used to treat infectious diseases since the early 20th century. However, the use of phage therapy today faces a number of challenges, primarily related to the limitations imposed by modern medical regulatory requirements and the insufficient development of effective therapeutic practices based on the principles of evidence-based medicine. This article provides an overview of current approaches to various therapeutic applications of bacteriophages
References
Law N, Aslam S. Phage therapy: Primer and role in the treatment of mdros. Current Infectious Disease Reports 2020;22. doi:10.1007/s11908-020-00742-x.
United States: Second national action plan for combating antibiotic-resistant bacteria 2020-2025. October 2020. p 31.
Barbu EM, Cady KC, Hubby B. Phage therapy in the era of Synthetic Biology. Cold Spring Harbor Perspectives in Biology 2016;8. doi:10.1101/cshperspect.a023879.
Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: A systematic review. The Lancet Infectious Diseases 2022;22. doi:10.1016/s1473-3099(21)00612-5.
Wright A, Hawkins CH, Änggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic‐resistant pseudomonas aeruginosa; a preliminary report of efficacy. Clinical Otolaryngology 2009;34:349–57. doi:10.1111/j.1749-4486.2009.01973.x.
Lebeaux D, Merabishvili M, Caudron E, Lannoy D, Van Simaey L, Duyvejonck H, et al. A case of phage therapy against Pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient. Viruses 2021;13:60. doi:10.3390/v13010060.
Paul K, Merabishvili M, Hazan R, Christner M, Herden U, Gelman D, et al. Bacteriophage rescue therapy of a vancomycin-resistant enterococcus faecium infection in a one-year-old child following a third liver transplantation. Viruses 2021;13:1785. doi:10.3390/v13091785.
Schoeffel J, Wang EW, Gill D, Frackler J, Horne B, Manson T, et al. Successful use of salvage bacteriophage therapy for a recalcitrant MRSA knee and hip prosthetic joint infection. Pharmaceuticals 2022;15:177. doi:10.3390/ph15020177.
Young MJ, Hall LML, Merabishvilli M, Pirnay J-P, Clark JR, Jones JD. Phage therapy for diabetic foot infection: A case series. Clinical Therapeutics 2023;45:797–801. doi:10.1016/j.clinthera.2023.06.009.
Pirnay J-P, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, et al. The phage therapy paradigm: Prêt-à-porter or sur-mesure? Pharmaceutical Research 2010;28:934–7. doi:10.1007/s11095-010-0313-5.
Łobocka M, Dąbrowska K, Górski A. Engineered bacteriophage therapeutics: Rationale, challenges and future. BioDrugs 2021;35:255–80. doi:10.1007/s40259-021-00480-z.
Chanishvili N. Phage therapy—history from twort and d’Herelle through Soviet experience to current approaches. Advances in Virus Research 2012:3–40. doi:10.1016/b978-0-12-394438-2.00001-3.
Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrobial Agents and Chemotherapy 2001;45:649–59. doi:10.1128/aac.45.3.649-659.2001.
Fruciano DE, Bourne S. Phage as an antimicrobial agent: D’herelle’s heretical theories and their role in the decline of phage prophylaxis in the West. Canadian Journal of Infectious Diseases and Medical Microbiology 2006;18:19–26. doi:10.1155/2007/976850.
Myelnikov D. An alternative cure: The adoption and survival of bacteriophage therapy in the USSR, 1922–1955. Journal of the History of Medicine and Allied Sciences 2018;73:385–411. doi:10.1093/jhmas/jry024.
Chanishvili N, Myelnikov D, Blauvelt TK. Professor Giorgi Eliava and the Eliava Institute of Bacteriophage. PHAGE 2022;3:71–80. doi:10.1089/phage.2022.0016.
Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011;1:66–85. doi:10.4161/bact.1.2.15845.
Nagel T, Musila L, Muthoni M, Nikolich M, Nakavuma JL, Clokie MR. Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world. Current Opinion in Virology 2022;53:101208. doi:10.1016/j.coviro.2022.101208.
Łusiak-Szelachowska M, Żaczek M, Weber-Dąbrowska B, Międzybrodzki R, Kłak M, Fortuna W, et al. Phage neutralization by Sera of patients receiving phage therapy. Viral Immunology 2014;27:295–304. doi:10.1089/vim.2013.0128.
Verbeken G, Pirnay J-P. European regulatory aspects of phage therapy: Magistral phage preparations. Current Opinion in Virology 2022;52:24–9. doi:10.1016/j.coviro.2021.11.005.
Yang Q, Le S, Zhu T, Wu N. Regulations of phage therapy across the world. Frontiers in Microbiology 2023;14. doi:10.3389/fmicb.2023.1250848.
Faltus T. The medicinal phage—regulatory roadmap for phage therapy under EU Pharmaceutical legislation. Viruses 2024;16:443. doi:10.3390/v16030443.
European Medicines Agency (2023). Committee for Medicinal Products for Human Use (CHMP), Concept Paper on the Establishment of a Guideline on the Development and Manufacture of Human Medicinal Products Specifically Designed for Phage Therapy, 4 December 2023, EMA/CHMP/BWP/486838/2023.
Order of the Ministry of Health of Ukraine dated 26.08.2005 No. 426 (as amended by the Order of the Ministry of Health of Ukraine dated 23.07.2015 No. 460) «Procedure for conducting the examination of registration materials for medicinal products submitted for state registration (re-registration), as well as the examination of materials regarding amendments to registration materials during the validity of the registration certificate».
Pirnay J-P, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: A multicentre, multinational, retrospective observational study. Nature Microbiology 2024;9:1434–53. doi:10.1038/s41564-024-01705-x.
Jones JD, Trippett C, Suleman M, Clokie MR, Clark JR. The future of clinical phage therapy in the United Kingdom. Viruses 2023;15:721. doi:10.3390/v15030721.
Pirnay J-P, Verbeken G, Ceyssens P-J, Huys I, De Vos D, Ameloot C, et al. The magistral phage. Viruses 2018;10:64. doi:10.3390/v10020064.
Köhler T, Luscher A, Falconnet L, Resch G, McBride R, Mai Q-A, et al. Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant pseudomonas aeruginosa. Nature Communications 2023;14. doi:10.1038/s41467-023-39370-z.
Ferry T, Kolenda C, Laurent F, Leboucher G, Merabischvilli M, Djebara S, et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal pseudomonas aeruginosa infection. Nature Communications 2022;13. doi:10.1038/s41467-022-31837-9.
Tan X, Chen H, Zhang M, Zhao Y, Jiang Y, Liu X, et al. Clinical experience of personalized phage therapy against carbapenem-resistant Acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease. Frontiers in Cellular and Infection Microbiology 2021;11. doi:10.3389/fcimb.2021.631585.
Yerushalmy O, Khalifa L, Gold N, Rakov C, Alkalay-Oren S, Adler K, et al. The Israeli Phage Bank (IPB). Antibiotics 2020;9:269. doi:10.3390/antibiotics9050269.
Fazal M-A, Agendia J, Yokoya K, Hannah M, Russell J, Alexander S. National Collection of Type Cultures: The bacteriophage and plasmid collections and repositories. Access Microbiology 2019;1. doi:10.1099/acmi.ac2019.po0308.
Willy C, Bugert JJ, Classen AY, Deng L, Düchting A, Gross J, et al. Phage therapy in Germany—update 2023. Viruses 2023;15:588. doi:10.3390/v15020588.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Annals of Mechnikov's Institute
This work is licensed under a Creative Commons Attribution 4.0 International License.
